Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza trivalent inactivated vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The influenza trivalent inactivated vaccine (IIV3 or TIV) is a synthetic biologic vaccine that contains three inactivated (killed) strains of the influenza virus—two type A strains (H1N1 and H3N2 subtypes) and one type B strain (Victoria lineage). It is administered by injection and works by stimulating the immune system to produce antibodies against these specific viral antigens. The primary indication is the prevention of seasonal influenza infection. The mechanism of action involves exposure to viral hemagglutinin proteins from each included strain; this induces an adaptive immune response without causing disease. Trivalent vaccines are recommended for all individuals aged 6 months and older. Multiple pharmaceutical companies develop and manufacture these vaccines globally[1][3][4][5].
- Brand names
- FluzoneFluarixAfluriaAgrippalBegripalFluazurSandovacAgrifluChirofluFluad Pediatric
- Other names
- trivalent influenza vaccineinactivated influenza vaccine trivalent
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Influenza trivalent inactivated vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza trivalent inactivated vaccine.